GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (FRA:BD5) » Definitions » Debt-to-EBITDA

BioDelivery Sciences International (FRA:BD5) Debt-to-EBITDA : 1.32 (As of Dec. 2021)


View and export this data going back to 2004. Start your Free Trial

What is BioDelivery Sciences International Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioDelivery Sciences International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was €4.1 Mil. BioDelivery Sciences International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was €47.9 Mil. BioDelivery Sciences International's annualized EBITDA for the quarter that ended in Dec. 2021 was €39.3 Mil. BioDelivery Sciences International's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2021 was 1.32.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for BioDelivery Sciences International's Debt-to-EBITDA or its related term are showing as below:

FRA:BD5' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.91   Med: -0.23   Max: 11.89
Current: 1.32

During the past 13 years, the highest Debt-to-EBITDA Ratio of BioDelivery Sciences International was 11.89. The lowest was -2.91. And the median was -0.23.

FRA:BD5's Debt-to-EBITDA is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.7 vs FRA:BD5: 1.32

BioDelivery Sciences International Debt-to-EBITDA Historical Data

The historical data trend for BioDelivery Sciences International's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioDelivery Sciences International Debt-to-EBITDA Chart

BioDelivery Sciences International Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.89 -2.91 4.66 1.94 1.32

BioDelivery Sciences International Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.38 2.14 1.50 1.32 1.32

Competitive Comparison of BioDelivery Sciences International's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, BioDelivery Sciences International's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioDelivery Sciences International's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioDelivery Sciences International's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BioDelivery Sciences International's Debt-to-EBITDA falls into.



BioDelivery Sciences International Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioDelivery Sciences International's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.084 + 47.947) / 39.42
=1.32

BioDelivery Sciences International's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.084 + 47.947) / 39.336
=1.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2021) EBITDA data.


BioDelivery Sciences International  (FRA:BD5) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


BioDelivery Sciences International Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BioDelivery Sciences International's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BioDelivery Sciences International (FRA:BD5) Business Description

Traded in Other Exchanges
N/A
Address
4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612
BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.

BioDelivery Sciences International (FRA:BD5) Headlines

No Headlines